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Nuclear receptors exert profound effects on mammary gland physiology and have complex
roles in the etiology of breast cancer. In addition to receptors for classic steroid hormones
such as estrogen and progesterone, the nuclear vitamin D receptor (VDR) interacts
with its ligand 1α,25(OH)2D3 to modulate the normal mammary epithelial cell genome
and subsequent phenotype. Observational studies suggest that vitamin D deficiency
is common in breast cancer patients and that low vitamin D status enhances the
risk for disease development or progression. Genomic profiling has characterized many
1α,25(OH)2D3 responsive targets in normal mammary cells and in breast cancers,
providing insight into the molecular actions of 1α,25(OH)2D3 and the VDR in regulation
of cell cycle, apoptosis, and differentiation. New areas of emphasis include regulation
of tumor metabolism and innate immune responses. However, the role of VDR in
individual cell types (i.e., epithelial, adipose, fibroblast, endothelial, immune) of normal
and tumor tissues remains to be clarified. Furthermore, the mechanisms by which VDR
integrates signaling between diverse cell types and controls soluble signals and paracrine
pathways in the tissue/tumor microenvironment remain to be defined. Model systems
of carcinogenesis have provided evidence that both VDR expression and 1α,25(OH)2D3
actions change with transformation but clinical data regarding vitamin D responsiveness of
established tumors is limited and inconclusive. Because breast cancer is heterogeneous,
analysis of VDR actions in specific molecular subtypes of the disease may help to
clarify the conflicting data. The expanded use of genomic, proteomic and metabolomic
approaches on a diverse array of in vitro and in vivo model systems is clearly warranted to
comprehensively understand the network of vitamin D regulated pathways in the context
of breast cancer.
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INTRODUCTION TO BREAST CANCER
In the United States in 2013, breast cancer was estimated to
account for 29% of new cancer cases and 14% of cancer deaths
in women, making it the most common cancer diagnosed and
the second most common cause of cancer mortality in women.
While standard tumor pathology focuses on the presence or
absence of hormone (estrogen, progesterone) and growth factor
(HER2) receptors, it is now clear that breast cancer is an extremely
heterogeneous disease. Genomic profiling has identified several
molecularly defined sub-types of breast cancer including Luminal
A, Luminal B, Basal, HER2, and Claudin-low (Cancer Genome
Atlas Network, 2012). The most frequently diagnosed sub-type is
Luminal A (51%), followed by Luminal B (29%), Basal (17%),
HER2 (12.5%), and Claudin-low (2%). The importance of these
molecular subtypes cannot be underestimated as they allow for
prediction of therapeutic targets and they display distinct clinical
courses (Caan et al., 2014). Women whose tumors fit the Luminal
A profile have the best prognosis whereas those whose tumors
have Luminal B or Basal profiles have poor prognosis. Although
many trials have assessed the impact of nutrients, including vita-
min D, on breast cancer risk and progression, few have been
designed to stratify results bymolecular sub-type. This review will
highlight the cumulative data on vitamin D actions in breast can-
cer while emphasizing the gaps in knowledge regarding its effects
on specific molecular subtypes.
OBSERVATIONAL AND INTERVENTION STUDIES ON
VITAMIN D AND BREAST CANCER
Population studies on vitamin D in relation to chronic diseases
such as breast cancer are complicated by difficulties in accurately
assessing dietary sources (confounders include natural foods vs.
fortified foods, supplement use, intake of D2 vs. D3, and calcium
status) and in estimating the amount of vitamin D3 generated
through sunlight exposure (confounders include lifestyle, lati-
tude, pollution, sunscreen, skin pigmentation, and age). Thus,
it is not surprising that studies designed to address the impact
of vitamin D status on breast cancer have yielded mixed results.
While much data is supportive that high vitamin D status as
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measured by serum 25-hydroxyvitamin D (25(OH)D3) is asso-
ciated with decreased risk of breast cancer (Bauer et al., 2013;
Bilinski and Boyages, 2013; Wang et al., 2013; Kim et al., 2014),
longer disease free survival and reduced mortality (Rose et al.,
2013; Maalmi et al., 2014; Mohr et al., 2014), some large stud-
ies have failed to support these associations (Kuhn et al., 2013).
With respect to endogenous synthesis of vitamin D3, small scale
studies supported the concept that sunlight exposure is associated
with reduced risk of breast cancer, however, the associations were
dependent on region of residence and skin pigmentation (John
et al., 1999, 2007). Larger international studies have consistently
demonstrated significant inverse correlations between incident
solar radiation and breast cancer rates (Edvardsen et al., 2011;
Engel et al., 2011, 2014; Grant, 2013; van der Rhee et al., 2013).
Data from randomized controlled trials (RCTs) of vitamin D
supplementation in relation to breast cancer development have
been inconclusive, with only slight benefits of supplementation
sometimes observed (Sperati et al., 2013; Redaniel et al., 2014).
The large (>30,000 women) Women’s Health Initiative (WHI)
trial assessed the impact of supplementation with both calcium
and vitamin D on multiple health outcomes including cancer.
However, the data from this trial was confounded by the low dose
of vitamin D (400 IU/day), coadministration of calcium supple-
ments, poor compliance, extensive pre-trial supplement use in the
study population and the freedom for trial participants to take
additional personal supplements of up to 1000 IU vitamin D per
day. Thus it was not surprising that initial data from theWHI trial
indicated no significant effects of vitamin D plus calcium sup-
plementation on breast cancer. Subgroup and follow-up analyses
of trial participants have yielded mixed results. One report indi-
cated that higher intake of vitamin D was moderately associated
with a lower risk of pre- but not post- menopausal breast can-
cer (Lin et al., 2007). In another sub-group analysis (including
only women who were not taking personal calcium or vitamin
D supplements at randomization), risk of invasive breast can-
cers was decreased in women supplemented with calcium and
vitamin D (Bolland et al., 2011). The most recent analysis of all
WHI diet study participants (assessed 5 years after intervention
ended) indicated a reduced incidence of in situ breast cancers in
the calcium and vitamin D cohort but also suggested that women
with the highest vitamin D intakes may have an increased risk
of invasive breast cancer (Cauley et al., 2013). Further sub-group
analysis based on menopausal status or molecular subtype may
shed light on these discrepancies. Regardless, these inconsistent
data emphasize the continued need for rigorous, well-designed
RCTs to specifically assess the impact of vitamin D supplementa-
tion on breast cancer development. Of note, the ongoing VITAL
trial of 20,000 men and women taking daily supplements of
2000 IU vitamin D3 (http://www.vitalstudy.org/) is monitoring
breast cancer as one outcome.
As discussed above, genomic studies have demonstrated that
breast cancers are heterogeneous and that different subtypes
exhibit distinct patterns of disease progression. It is likely that
VDR expression or function and thus sensitivity to changes in
vitamin D status may be subtype specific, yet this has not rig-
orously been examined. The limited epidemiologic data that has
been stratified by subtype is mixed - one study reported that the
relationship between serum 25(OH)D and reduced risk of breast
cancer was strongest for high grade, ER negative or triple nega-
tive cancers (Yao and Ambrosone, 2013) whereas another found
that low serum 25(OH)D was associated with poor prognosis
only in women with the luminal subtype of breast cancer (Kim
et al., 2011). It should be noted that while vitamin D deficiency
is common in all breast cancer patient populations, it is partic-
ularly prevalent in those with triple negative/basal-like tumors,
the most aggressive form of the disease (Rainville et al., 2009;
Peppone et al., 2012; Yao and Ambrosone, 2013). Even without
rigorous “proof” of a beneficial effect of supplemental vitamin D
on breast cancer, correction of vitamin D deficiency in women at
risk for, or living with, breast cancer should be standard practice.
VITAMIN D PATHWAY EXPRESSION IN NORMAL MAMMARY
CELLS AND BREAST CANCER PREVENTION
The VDR is present in rat, mouse and human mammary gland
and its expression is highest during puberty, pregnancy and lac-
tation (Berger et al., 1987; Zinser et al., 2002). In actively growing
murine mammary ducts, VDR expression is high in the duc-
tal epithelium and low in the proliferating terminal end buds.
Consistent with this murine data, high content immunohisto-
chemistry of normal human breast epithelium demonstrated that
VDR positive cells are exclusively found in the luminal (differ-
entiated) cell layer and do not co-localize with proliferating Ki67
positive cells (Santagata et al., 2014). VDR has also been identified
in the stromal compartment including the mammary fibrob-
lasts and adipocytes (Ching et al., 2011; Campos et al., 2013;
Knower et al., 2013), highlighting the complexity of 1,25(OH)2D3
signaling in the breast tissue environment.
In addition to VDR, the 25(OH)D activating enzyme
CYP27B1 is expressed in murine and human mammary tis-
sue (Zinser and Welsh, 2004a; Townsend et al., 2005; Kemmis
et al., 2006; Peng et al., 2009), suggesting that systemic 25(OH)D
delivered to the mammary gland can be converted to the biolog-
ically active VDR ligand 1,25(OH)2D3. In vitro studies confirm
that incubation of mammary epithelial cells with physiologi-
cal (nanomolar) concentrations of 25(OH)D leads to tempo-
ral increases in 1,25(OH)2D3 detected in tissue culture media
(Kemmis et al., 2006). Although there is still uncertainty regard-
ing how 25(OH)D, which circulates tightly bound to the vitamin
D binding protein (DBP), is internalized by non-renal cells, the
presence of megalin and cubilin (Rowling et al., 2006) indicates
that these accessory proteins could mediate uptake of 25(OH)D-
DBP complexes in mammary gland as has been demonstrated for
renal cells(Willnow and Nykjaer, 2002). Indeed, in vitro studies
demonstrate that normal breast epithelial cells and some breast
cancer cells internalize 25(OH)D via megalin-mediated endocy-
tosis (Rowling et al., 2006), however, the function of this uptake
pathway in intact mammary gland has yet to be confirmed.
CYP27B1 is also expressed in mammary adipocytes, which too
are capable of converting 25(OH)D to 1,25(OH)2D3 in organoid
culture (Ching et al., 2011). Collectively, these studies provide a
biological link between vitamin D status [i.e., serum 25(OH)D]
and breast cancer risk that is observed at the population level.
The functions of CYP27B1 and VDR in prevention of breast
cancer are supported by data from animal models. In vivo, both
Frontiers in Physiology | Integrative Physiology June 2014 | Volume 5 | Article 213 | 2
Narvaez et al. Vitamin D in breast cancer
high dietary vitamin D (Jacobson et al., 1989) and treatment with
synthetic VDR agonists (Hussain et al., 2003) inhibit the devel-
opment of carcinogen induced mammary tumors. Furthermore,
VDR ablation enhances the development of hyperplasias and
hormone independent mammary tumors after DMBA admin-
istration, and VDR haploinsufficiency sensitizes the mammary
gland to tumorigenesis driven by the neu oncogene (Zinser et al.,
2002; Zinser and Welsh, 2004b). In organ culture models, VDR
agonists such as 25(OH)D3 and 1α,25(OH)2D3 reduce the inci-
dence of DMBA induced pre-neoplastic lesions (Mehta et al.,
1997; Peng et al., 2009) suggesting direct anti-cancer effects of
these metabolites on mammary tissue. Collectively, these data
support the concept that systemic 25(OH)D delivered to mam-
mary gland is converted to 1,25(OH)2D3 which activates VDR to
protect against carcinogenesis.
Despite these consistent data, the precise mechanisms by
which vitamin D inhibits cancer development have yet to be
discerned. Both 25(OH)D3 and 1α,25(OH)2D3 exert profound
effects on non-tumorigenic VDR positive mammary epithe-
lial cells including inhibition of hormone stimulated growth
and branching morphogenesis and induction of differentiation
biomarkers such as E-cadherin. VDR and CYP27B1 expression in
mammary adipocytes also contribute to the anti-cancer effects in
the whole tissue, since in response to 25(OH)D adipocytes secrete
diffusible signals that inhibit morphogenesis of the adjacent duc-
tal epithelium (Ching et al., 2011). Other potential mechanisms
for breast cancer prevention by vitamin D include reduction in
DNA damage (possibly via up-regulation of p53 signaling), sup-
pression of oxidative stress and inhibition of angiogenesis, many
of which have been demonstrated in tissues or cell types other
than mammary gland (Kallay et al., 2002; Peng et al., 2010; Bruce
et al., 2011; Hopkins et al., 2011; Krishnan and Feldman, 2011;
Bikle, 2012; Dogan et al., 2012; Gordon-Thomson et al., 2012;
Ting et al., 2012; Alvarez et al., 2014; Nakai et al., 2014; Sun
et al., 2014; Uberti et al., 2014; Zhong et al., 2014). In addition,
recent data from our group and others implicate alteration of
cellular energy metabolism and innate immune responses in the
anti-cancer effects of vitamin D signaling on non-tumorigenic
mammary epithelial cells as described below.
Although initially recognized by Otto Warburg more than 50
years ago (Warburg, 1956), attention has recently been re-focused
on the role of cellular energy metabolism as a critical compo-
nent of tumor initiation and progression. It is now recognized
that many cancer cells preferentially rely on glycolysis to generate
energy and macromolecules that are essential for rapid prolifer-
ation, even in the presence of normoxia. The metabolic switch
(the “Warburg effect”) from oxidative phosphorylation to aerobic
glycolysis is triggered in normal cells by activation of oncogenes
and/or loss of tumor suppressors which, in part, target glucose
and glutamine metabolism. The best characterized oncogenic
driver of the metabolic switch, myc, induces a cohort of genes that
promote glycolysis and alter glutamine flux. Conversely, tumor
suppressors such as p53 normally suppress glycolysis and enhance
flux through the tricarboxylic acid (TCA) cycle and oxidative
phosphorylation. p53 also increases intracellular glutamate which
is shunted toward glutathione synthesis, enhancing antioxidant
defense against reactive oxygen species. Recent studies support
the concept that vitamin D might target energy utilization path-
ways in non-tumorigenic breast cells to prevent carcinogenesis.
The regulation of cellular glucose metabolism by 1,25(OH)2D3
has been studied (Zheng et al., 2013) in pre-malignant mam-
mary cells (MCF10A cells) compared to their ras transformed
malignant derivatives (MCF10A-ras cells). In this model, 4-day
1,25(OH)2D3 treatment reduced flux of glucose through gly-
colysis in both MCF10A and MCF10A-ras cells, with a more
pronounced effect in the transformed cells. 1,25(OH)2D3 also
reduced the flux of glucose to acetyl-coA and oxaloacetate in
both cell lines, suggesting a reduction in TCA cycle activity. The
predicted consequences of these 1,25(OH)2D3 inducedchanges
would be limitation in the availability of TCA-derived precur-
sors for macromolecule synthesis, coincident with reduction in
proliferation.
In microarray profiling of non-tumorigenic mammary epithe-
lial cells (hTERT-HME1) cells, we identified SLC1A1, which
encodes a plasma membrane glutamate transporter, and GLUL,
which encodes glutamine synthetase (GS) as novel 1,25(OH)2D3
targets. We validated that 1,25(OH)2D3 increases SLC1A1
mRNA (>10-fold) and decreases GLUL mRNA (>4-fold) in
these cells, and also demonstrated decreased expression of
the cognate proteins GS and SLC1A1 by western blotting.
These changes in metabolic gene/protein expression corre-
lated with accumulation of glutathione and changes in res-
piratory capacity in 1,25(OH)2D3 treated cells. Furthermore,
1,25(OH)2D3 pretreatment hindered growth of hTERT-HME1
cells in glutamine-starved media and exogenous glutamine par-
tially rescued 1,25D-mediated growth arrest. These findings are
intriguing because: (a) glutamate uptake and glutamate trans-
porters are enhanced during differentiation and deregulated in
cancer cells; (b) SLC1A1 null mice exhibit GSH deficiency and
high oxidative stress; (c) GS enzymatic activity is necessary for
adaption of mammary cells to glutamine depletion; and (d) data
compiled from The Human Protein Atlas indicates that SLC1A1
is reduced and GLUL is increased in human breast cancers relative
to normal tissue. Thus, we propose that 1,25(OH)2D3 regula-
tion of SLC1A1 and GLUL synergizes with p53 to alter metabolic
flux, prevent the myc-driven metabolic switch and induce qui-
escence in normal mammary epithelial cells. Collectively, these
emerging data demonstrating regulation of amino acid and glu-
cose metabolism (Zheng et al., 2013) in mammary epithelial
cells by 1,25(OH)2D3 provides another mechanism by which
vitamin D may act to prevent carcinogenesis in normal breast
tissue. These changes may be complemented by alterations in
lipid and energy metabolism in adjacent stromal adipocytes by
1,25(OH)2D3 (Welsh et al., 2011; Narvaez et al., 2013).
Another emerging area in cancer prevention by vitamin
D involves suppression of inflammation. We identified CD14,
a component of the innate immune system, as the second
most highly upregulated gene (second only to CYP24A1) in
1,25(OH)2D3 treated hTERT-HME1 cells. CD14 is a known VDR
target in macrophages and other immune cells, but its regulation
by 1,25(OH)2D3 in mammary cells has not been well studied.
In contrast to macrophages where 1,25(OH)2D3 induces mem-
brane bound CD14, both 1,25(OH)2D3 and 25(OH)D3 induce
the secretion of large quantities of soluble CD14 (sCD14) from
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mammary epithelial cells. As a pattern recognition receptor,
sCD14 binds lipopolysaccharide and contributes to protection
against mastitis in mammary tissue (Lee et al., 2003; Zheng
et al., 2006; Wall et al., 2009). The soluble form of CD14 is
also secreted into human milk where it contributes to protection
of the neonatal gut from infections (Vidal and Donnet-Hughes,
2008). However, even in the absence of infection or lactation,
CD14 and other genes involved in innate immunity are highly
induced during regression of the mammary gland after wean-
ing (Stein et al., 2004). The role of CD14 during this period of
glandular remodeling may be the recognition and disposal of
apoptotic cells (Heidenreich, 1999; Devitt et al., 2004; Tennant
et al., 2013). We speculate that vitamin D induction of solu-
ble CD14 in mammary tissue inhibits activation of tissue resi-
dent macrophages, suppressing inflammation which is known to
drive cancer development and progression(McMahon et al., 2011;
Simpson and Brown, 2013). However, it remains to be deter-
mined whether vitamin D status regulates any of these proposed
functions of CD14 in mammary tissue in vivo. One caveat to
future experimentation on vitamin D regulation of CD14 is the
apparent discordance between the human and murine genomes.
1,25(OH)2D3 does not induce CD14 in the murine mammary
epithelial cell line HC11 and CD14 gene expression is not altered
in the mammary gland of VDRKO mice (Welsh, unpublished).
VITAMIN D PATHWAY EXPRESSION IN ESTABLISHED
BREAST CANCER
Over 30 years ago, the recognition that VDR expression was
retained in breast cancers prompted extensive studies to deter-
mine whether targeting VDR in tumors would provide therapeu-
tic benefit. VDR expression is retained in the majority of rodent
breast tumors, human breast cancers and established breast can-
cer cell lines (Colston et al., 1986; Buras et al., 1994; Zinser and
Welsh, 2004b). In a study of 136 patients with primary breast
cancer, it was found that women with VDR negative tumors
relapsed significantly earlier than women with VDR positive
tumors (Berger et al., 1991). Of note, some data suggests that
receptor protein expression declines in highly aggressive tumors
(Lopes et al., 2010). We reviewed the frequency of genomic VDR
changes in human breast cancers using datasets publically avail-
able on The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/
tcga/) which annotates mutations, amplifications, deletions and
mRNA expression profiles in human tumors (Table 1). Analysis
of the TCGA invasive breast cancer dataset (Cancer Genome Atlas
Network, 2012) of over 450 breast tumors suggests that alterations
in the VDR gene are rare in human breast cancer. As shown in
Table 1, only 5% of human breast tumors exhibited any alter-
ation in VDR sequence or expression. However, when the VDR
gene was altered, the most common change was a reduction in
mRNA expression (deletions and mutations did not occur). With
respect to VDR expression in specific molecular sub-types, the
Luminal B subtype had the highest frequency of VDR alterations
with 10.5% of tumors displaying reduced VDRmRNA expression
compared to 0–3% for Luminal A, Basal, HER2, or Claudin-
Low subtypes. These results showing retention of VDR in the
majority of human breast tumors are consistent with the data of
Santagata et al. (2014) who used a multiplex immunohistochem-
ical approach to map receptor proteins at the single cell level and
confirmed that the majority of human breast tumors are VDR
positive. Interestingly, this study also demonstrated that breast
tumors with the highest expression of VDR, ER, and Androgen
Receptor (AR) had the best prognosis. The retention of VDR in
tumors may indicate that its function has been somehow abro-
gated, either by altered function of the VDR despite mutation
(i.e., alteration of transcriptional co-regulators), reduced ligand
availability (i.e., loss of CYP27B1 and/or gain of CYP24A1), or
mutation/deregulation of critical anti-cancer VDR target genes.
Despite these data, in vitro studies have demonstrated
that specific oncogenes can deregulate VDR expression. For
instance, comparison of VDR expression in a series of isogenic,
Table 1 | Frequency of genomic alterations in VDR and CYP24A1 derived from The Cancer Genome Atlas dataset of human breast tumors.
All tumors (n = 463) Lum A (n = 235) Lum B (n = 133) Basal (n = 81) HER2 (n = 58) CLN Lo (n = 8)
VDR
% Alterations 5.2 3.4 11.3 4.9 3.4 0
Amplifications 0.4 0 0.8 1.2 0 0
Deletions 0 0 0 0 0 0
Mutations 0 0 0 0 0 0
↓ mRNA 3.9 3.0 10.5 3.7 0 0
↑ mRNA 0.9 0.4 0 0 3.4 0
CYP24A1
% Alterations 9.7 9.8 11.3 7.4 10.3 12.5
Amplifications 5.6 4.7 9.8 1.2 10.3 0
Deletions 0.2 0.2 0 0 0 0
Mutations 0.4 0.2 0.8 0 0 0
↓ mRNA 0 0 0 0 0 0
↑ mRNA 3.5 4.7 0.8 6.2 0 12.5
The data was calculated with the publically available breast invasive carcinoma dataset (Cancer Genome Atlas Network, 2012) at https://tcga-data.nci.nih.gov/tcga/as.
Numbers indicate the percentage of the indicated genomic alterations observed in the total number of tumors analyzed within each group (shown in parentheses).
LumA, Luminal A; LumB, Luminal B; CLN Lo, Claudin Low.
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progressively transformed human mammary epithelial (HME)
cell lines indicated that VDR expression and function was reduced
more than 70% in HME cells expressing SV40 and/or RAS com-
pared to the non-transformed HME cells from which they were
derived (Kemmis and Welsh, 2008). Likewise, SV40 and RAS
have been shown to reduce VDR activity in other breast cancer
cell model systems (Agadir et al., 1999; Escaleira and Brentani,
1999). Transcriptional repressors linked to the epithelial mes-
enchymal transition such as SNAIL and SLUG have also been
shown to down-regulate VDR (Mittal et al., 2008; Larriba et al.,
2010). Thus, it is clear that there are distinct mechanisms target-
ing both the VDR gene itself and its protein product. Data on
receptor expression derived fromwhole tumorsmay be somewhat
misleading since cancer progression is driven by genetic insta-
bility and outgrowth of cells with advantageous mutations, such
as activation of oncogenes. These studies indicate that abrogated
expression and/or function of VDRmay be limited to certain sub-
sets of cells within individual tumors that have sustained specific
molecular genetic alterations.
In addition to genetic alterations and effects of oncogenes,
VDR abundance is affected by many physiological agents, includ-
ing 1,25(OH)2D3 itself, estrogens, retinoids and growth factors.
Thus, cell sensitivity to 1,25(OH)2D3 may also reflect the activ-
ity of other hormone signaling pathways through their impact on
VDR expression. In breast cancer, the regulation of VDR expres-
sion and activity by estrogens is likely to be clinically significant.
ER positive cells tend to express higher levels of VDR than ER
negative cells (Buras et al., 1994) and in vitro studies have demon-
strated that estrogen up-regulates whereas anti-estrogens down
regulate VDR in ER positive breast cancer cells (Nolan et al., 1998;
Byrne et al., 2000). Further studies are therefore warranted to
determine the degree to which estrogen status influences VDR
abundance in different 1,25(OH)2D3 target tissues (i.e., breast,
bone, uterus), and whether common therapeutic synthetic or nat-
ural estrogens act as estrogen agonists or antagonists in regulation
of VDR expression. Consistent with this concept, some data sug-
gests that phytoestrogens such as resveratrol and genestein can
alter VDR expression and 1,25(OH)2D3 sensitivity in cancer cells
in vitro (Wietzke and Welsh, 2003; Gilad et al., 2006).
Other tumor-associated changes that can lead to 1,25(OH)2D3
resistance in VDR positive tumors include disruption of VDR
transcriptional activation and enhanced catabolism of its lig-
and. Data from breast, bladder and prostate cancer suggests that
alterations in transcriptional co-regulators can abrogate signal-
ing by the 1,25(OH)2D3-VDR complex (Malinen et al., 2008;
Abedin et al., 2009). Enhanced mammary cell catabolism of
1,25(OH)2D3 would also be predicted to limit the formation of
active VDR complexes. Indeed, amplification of the CYP24A1
gene was reported in human breast tumors (Albertson et al.,
2000) and analysis of the datasets from The Cancer Genome
Atlas confirms that a subset of human breast cancers (10–13%)
exhibit alterations in the CYP24 gene, with the most frequent
changes being amplifications and upregulation at the mRNA level
(Table 1). There is no obvious subtype specificity to CYP24A1
changes, although amplifications were somewhat more frequent
in Luminal B and HER2 subtypes whereas increased mRNA lev-
els were more common in Basal and Claudin-low tumors. These
data are consistent with analysis of tumor samples which demon-
strated higher CYP24A1 protein expression in breast tumors
compared to adjacent normal tissue (Townsend et al., 2005; Lopes
et al., 2010). Furthermore, splicing variants of CYP24A1 have
been reported in breast cancer cell lines (Scheible et al., 2014),
suggesting that distinct forms of the enzyme with altered proper-
ties may be expressed in tumors. The significance of the CYP24A1
deregulation with respect to overall catabolism of vitamin D
metabolites in situ has yet to be ascertained.
Given that normal mammary cells utilize 25(OH)D3 as sub-
strate for local tissue generation of 1,25(OH)2D3, imbalanced
expression of either CYP24A1 or CYP27B1 favoring catabolism
could theoretically contribute to escape of developing tumor
cells from anti-cancer VDR signaling. In the HME cell model,
oncogenic transformation was associated with reduced CYP27B1
expression and activity [as measured by 1,25(OH)2D3 synthe-
sis]. The reductions in CYP27B1 in the oncogene-transformed
HME cells were of sufficient magnitude to reduce cellular sensi-
tivity to growth inhibition by 25(OH)D3 approximately 100-fold
(Kemmis and Welsh, 2008). However, clinical data on CYP27B1
expression in breast cancer is inconsistent (Segersten et al., 2005;
Townsend et al., 2005; de Lyra et al., 2006; McCarthy et al., 2009;
Lopes et al., 2010) and less than 2% of breast cancers annotated
in The Cancer Genome Atlas datasets exhibit genomic alter-
ations in CYP27B1. However, altered splice variants of CYP27B1
have been detected in breast cancer cells (Cordes et al., 2007;
Fischer et al., 2007) suggesting the possibility that forms of the
CYP27B1 enzyme with altered function could be expressed in
breast tumors.
ACTIONS OF VDR AGONISTS ON BREAST CANCER CELLS
AND TUMORS
Numerous studies have profiled the cellular and molecular
effects of 1,25(OH)2D3 on VDR positive breast cancer cells.
Furthermore, a large number of structural analogs of vita-
min D developed by pharmaceutical companies and academic
researchers have been used to probe the mechanisms of vitamin
Dmediated growth inhibition. In general, the effects of VDR ago-
nists on breast cancer cells include modulation of key cell cycle
regulators to induce G0/G1, induction of differentiation mark-
ers, and/or activation of cell death (via apoptosis or autophagy).
Notably, studies with cells derived from VDRKO mice has def-
initely established that the nuclear VDR is required for the
anti-proliferative and pro-apoptotic effects of 1,25(OH)2D3 in
transformed mammary cells in vitro (Zinser et al., 2003; Valrance
et al., 2007). In addition to regulation of cell growth and sur-
vival, studies in ER negative breast cancer cells, representative
of late stage disease, have provided evidence that 1,25(OH)2D3
alters genomic stability, inhibits angiogenesis and reduces inva-
sion and metastasis. For instance, 1,25(OH)2D3 interacts with
the 53BP1 protein to eliminate invasive breast cancer cells lacking
BRCA1 (Grotsky et al., 2013). 1,25(OH)2D3 and analogs inhibit
invasion as measured by the Boyden chamber assay (Flanagan
et al., 2003) likely through suppression of extracellular proteases
(MMP-9, urokinase-type plasminogen activator, tissue type plas-
minogen activator), protease inhibitors and adhesion molecules.
Comparative studies of breast tumors and normal adjacent breast
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tissue in an explant system confirmed that malignant tissue
is responsive to 1,25(OH)2D3 but that the magnitude of the
response is highly disparate between individual patients (Suetani
et al., 2012; Milani et al., 2013). Furthermore, tumor tissue was
far less sensitive to 25(OH)D3 than 1,25(OH)2D3 (Suetani et al.,
2012).
Animal models of established breast cancer have demonstrated
that VDR agonists can reduce tumor growth (and in some cases
trigger tumor regression) with minimal effects on calcemia [the
most common and dangerous side effect of 1,25(OH)2D3 ther-
apy]. In experimental metastasis paradigms, the vitamin D analog
EB1089 inhibited secondary tumors, blocked skeletal metas-
tases and improved survival (El Abdaimi et al., 2000; Flanagan
et al., 2003). More recently, dietary modifications have been
shown to alter breast tumor growth and progression. Increasing
dietary vitamin D3 from 1000 IU/kg diet (rodent standard) to
5000 IU/kg diet significantly reduced growth of established MCF-
7 xenografts, with equivalent potency to 1,25(OH)2D3 (Swami
et al., 2012). In another study, vitamin D deficiency sufficient to
enhance bone turnover promoted the skeletal growth of breast
cancer metastases (Ooi et al., 2010). For further details on these
and other in vivo studies, several recent comprehensive reviews on
vitaminD and breast cancer are available (Krishnan and Feldman,
2011; Lopes et al., 2012; Welsh, 2012).
GENOMIC PROFILING OF VDR AGONISTS IN BREAST
CANCER MODEL SYSTEMS
Screening for molecular changes induced by 1,25(OH)2D3 or
vitamin D analogs in various breast cancer cells has identified
scores of VDR regulated genes and proteins, indicating a broad
range of downstream targets. Here we will focus on the few com-
prehensive genomic studies that have allowed for identification
of vitamin D responsive pathways in breast cancer (Lee et al.,
2006; Campos et al., 2013; Milani et al., 2013; Laporta and Welsh,
2013). In the first study of vitamin D mediated genomic changes
in breast cancer, Feldman’s groups used early generation arrays
to compare gene expression in ER positive MCF-7 cells and ER
negative MDA-MB-231 cells treated with 100 nM 1,25(OH)2D3
(Swami et al., 2003). Due to the limited nature of these arrays,
which comprised 2000 cancer related genes, direct comparisons
with whole genome profiling arrays isn’t appropriate. However,
comparisons between the two cell lines is of interest. Using a
2-fold cutoff, 62 genes (47 up/15 down) in MCF-7 cells and
20 genes in MDA-MB-231 cells (10 up/10 down) were signifi-
cantly altered by 24 h treatment with 100 nM 1,25(OH)2D3, with
only seven genes commonly altered in both cell lines. The larger
number of regulated genes in MCF-7 cells was not surprising as
CYP24A1 induction was 10-fold higher in MCF-7 cells (52-fold)
than in MDA-MB-231 cells (5.5-fold). Other highly regulated
genes in MCF-7 cells treated with 1,25(OH)2D3 for 24 h included
RBL2, CTNNA1, RAD23B, NCOA4, BMP5 and IFNG (up) and
CEACAM1, CDH6, IL13, IL1R2 and ESR (down). In MDA-MB-
231 cells, highly modulated genes at 24 h included CASP4, NF1B,
ITGAV, TXNRD1 and TGFB2 (up) and ANGPT1, four MMPs
(12, 10, 7, 1) and PRKD1 (down). Thus, in MCF-7 cells, many
of the 1,25(OH)2D3 regulated genes were involved in growth fac-
tor signaling, cell cycle, apoptosis and immune responses, whereas
in MDA-MB-231 cells genes related to disease progression (i.e.,
invasion and angiogenesis) were altered.
Since the availability of whole genome arrays, four studies (Lee
et al., 2006; Campos et al., 2013; Milani et al., 2013; Laporta
and Welsh, 2013) on the effects of VDR agonists [three with
1,25(OH)2D3, one with a synthetic VDR agonist] in breast can-
cer model systems have reported although only one of these
datasets (Milani et al., 2013, accession #GSE27220) is publically
available on the Gene Expression Omnibus website (http://www.
ncbi.nlm.nih.gov/geo/). Lee et al. (2006) compared the effects of
1 nM RO3582, a Gemini 1,25(OH)2D3 analog, on pre-malignant
(MCF10AT1) and malignant (MCF10CA1a) breast cancer cells
and identified distinct gene expression profiles for each cell line.
Similar to the comparison of MCF-7 and MDA-MB-231 cells
(Swami et al., 2003), more significant changes in gene expres-
sion were observed in the less malignant MCF10AT1 cells than
in the invasive MCF10CA1a cells (391 vs. 156, respectively, 12 h
treatment; 2-fold cutoff). Despite the reduced sensitivity in the
more aggressive cells, the overlap in target genes was considerable
(about 55% of the genes altered in MCF10AT1 cells were simi-
larly altered in the MCF10CA1a cells); the complete gene lists are
available as supplemental data.
Using an approach designed to more accurately represent
the tumor microenvironment in situ, tumor slices from post-
menopausal breast cancer patients with stage I, II, or III breast
cancer were cultured with 0.5 or 100 nM 1,25(OH)2D3 for
24 h (Milani et al., 2013). This study identified nine genes that
were significantly altered within 24 h of exposure to 0.5 nM
1,25(OH)2D3, a concentration that is physiologically achievable
in patients. Of these, CYP24A1 was induced over 7-fold and
was validated in another set of tumor samples, clearly indicat-
ing activation of VDR signaling. Gene set enrichment analy-
sis (GSEA) indicated a trend toward the enrichment of genes
sharing DR3 binding sites, a consensus motif for VDR. Other
genes identified in response to 0.5 nM 1,25(OH)2D3 included
DPP4, CYP26B1, SPIN3, KCKN3, EFTUD1, TKTL1, and CA2
(up-regulated) and FCGR2C and SAMSN1 (down-regulated). At
100 nM 1,25(OH)2D3, 30 genes (28 up/2 down) were significantly
regulated by 1,25(OH)2D3. In addition to those listed above,
genes up-regulated by 3-fold or more included IL1RL1, CILP,
PI15, TMEM37, and SHE. The two top down-regulated genes
(2-fold or more) were P2RY1 and BCOR. Interestingly, CD14
and SLC1A1, two 1,25(OH)2D3 regulated genes we identified in
the genomic profiles of normal mammary epithelial cells dis-
cussed above, were also induced by 1,25(OH)2D3 in the breast
cancer slice model. The significance of this study is that it demon-
strated for the first time that 1,25(OH)2D3 could induce genomic
changes in intact breast tumor tissue, indicating the functionality
of the VDR. Although patient-to-patient variability was consider-
able, a core set of 1,25(OH)2D3 modulated genes was identified
that may represent biomarkers of vitamin D action for future
studies.
A fourth genomic study was recently conducted in a mouse
mammary tumor model of triple negative breast cancer (Laporta
and Welsh, 2013). Cells derived from DMBA induced tumors
generated in wildtype (WT) and VDRKO mice were studied
after 24 h treatment with 100 nM 1,25(OH)2D3. A unique feature
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of this study was the inclusion of VDRKO cells in which the
growth inhibitory effects of 1,25(OH)2D3 were restored via sta-
ble expression of human VDR (KOhVDR cells). Genomic profiling
demonstrated that 1,25(OH)2D3 failed to alter gene expression
in VDRKO cells whereas major changes were observed in cells
derived from WT mice (WT145 cells) and in KOhVDR cells. With
a 2-fold cutoff, 117 transcripts inWT145 cells and 197 transcripts
in the KOhVDR clones were significantly altered by 1,25(OH)2D3
with 35 genes found to be commonly regulated in all VDR-
positive cell lines (the complete list of genes is included in the
manuscript). In addition to Cyp24a1, seven genes were validated
as 1,25(OH)2D3 responsive and VDR dependent in this sys-
tem: Cib2, Prelp, Enpp1, Plau, Hbegf, Postn, and Has2. The last
four of these, whose expression was markedly down regulated
by 1,25(OH)2D3, are known to drive breast cancer invasion and
metastasis. These data support a model whereby 1,25(OH)2D3
coordinately suppresses multiple proteins that are required for
survival of triple-negative/basal-like breast cancer cells.
In summary, while CY24A1 is commonly identified in
microarray studies as the most highly upregulated gene in
1,25(OH)D treated cells, other target genes vary greatly depend-
ing on the model system. Integration of the existing genomic
datasets generated in various mammary cell models with other
normal and transformed array profiles and ChIP-Seq studies
will assist in identifying common and tissue/cell specific genesets
regulated by the 1,25(OH)2D3-VDR complex. In addition, the
ENCODE project (http://genome.ucsc.edu/ENCODE/cellTypes.
html) includes several breast cancer cell lines (MCF-7, MDA-MB-
231, T47-D) whichmay provide relevant genomic information on
nuclear receptor signaling The continued use of complex models
such as tumor explants for vitamin D studies is desirable given the
expression of VDR in most cell types and the critical interactions
between tumor cells and their stromal microenvironment.
CONCLUSIONS
Although meta-analyses of population studies demonstrate an
inverse relationship between vitamin D status and breast cancer
risk, questions remain regarding mechanisms, tissue specificity,
and optimal intakes of vitamin D3 for potential benefits on can-
cer. In 2010, the Institute of Medicine recommended an increase
in the adult intake of vitamin D3 (from 200 to 600 IU per day)
based on its role in bone health, but concluded that current data
is insufficient to support recommendations with respect to can-
cer prevention. Comprehensive genomic, metabolomic and pro-
teomic profiling approaches combined with mechanistic studies
remain highly valuable for identification of relevant biomark-
ers of tissue vitamin D action that are needed for translational
investigations (i.e., supplementation trials).
FUTURE VIEW
Despite the extensive effort to understand the relationship
between vitamin D and breast cancer, many issues remain unre-
solved. Much of the work conducted in cell systems or animal
models is consistent, but epidemiological data is somewhat mixed
and clinical studies are limited. As discussed above, popula-
tion studies do support the concept that high serum levels of
1α,25(OH)2D3 and/or its precursor 25(OH)D3 are associated
with lower risk of initial disease development andmay retard pro-
gression. However, tissue uptake and cellular metabolism of these
metabolites in vivo is likely to be highly relevant to cancer biol-
ogy, yet few studies have successfully measured these parameters.
In addition, there is little data on how systemic vitamin D sta-
tus might interact with other known breast cancer risk factors
including genetic (BRCA1, BRCA2, ATM), endocrine (estrogen,
progesterone) and environmental (radiation, carcinogens) mod-
ulators of breast cancer development. Genomic profiling has
characterized many 1α,25(OH)2D3 responsive targets in nor-
mal mammary cells and in breast cancers providing valuable
insight into the molecular actions of 1α,25(OH)2D3 and the
VDR in regulation of cell cycle, apoptosis and differentiation.
New areas of emphasis suggested by recent studies include reg-
ulation of tumor metabolism and activation of innate immune
responses. However, the role of VDR in individual cell types
(ie epithelial, adipose, fibroblast, endothelial, immune) of nor-
mal and tumor tissues remains to be clarified. Furthermore,
there has been limited attention directed at understanding how
VDR integrates signaling between these diverse cell types and
what soluble signals and paracrine pathways may be regulated
by 1α,25(OH)2D3 in the tissue and tumor microenvironment.
Finally, the possible interactions of VDR with other nuclear
receptors and their ligands (particularly RXR family) in con-
trol of mammary cell fate/carcinogenesis will require additional
study.
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